---
title: 'The Alliance Between the German Cancer Research Center and Bayer: A Retrospective
  of an Innovative Collaboration Model'
date: '2024-08-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39177747/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240824182422&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: In 2009, the German Cancer Research Center (DKFZ) and the biopharmaceutical
  company Bayer AG initiated an academic-industry co-discovery collaboration. The
  partners combined their expertise in tumor biology and drug discovery to identify
  and validate novel targets for cancer treatment. In the early phase of the Alliance,
  the focus was on target identification and validation projects. Over time, both
  partners realized that they could also successfully collaborate on later stages
  of ...
disable_comments: true
---
In 2009, the German Cancer Research Center (DKFZ) and the biopharmaceutical company Bayer AG initiated an academic-industry co-discovery collaboration. The partners combined their expertise in tumor biology and drug discovery to identify and validate novel targets for cancer treatment. In the early phase of the Alliance, the focus was on target identification and validation projects. Over time, both partners realized that they could also successfully collaborate on later stages of ...